A detailed history of Parallel Advisors, LLC transactions in Galapagos Nv stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,497 shares of GLPG stock, worth $38,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,497
Previous 837 78.85%
Holding current value
$38,398
Previous $20,000 115.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$24.2 - $30.67 $15,972 - $20,242
660 Added 78.85%
1,497 $43,000
Q2 2024

Aug 08, 2024

BUY
$24.78 - $32.48 $18,535 - $24,295
748 Added 840.45%
837 $20,000
Q1 2024

May 06, 2024

SELL
$32.2 - $42.44 $10,014 - $13,198
-311 Reduced 77.75%
89 $2,000
Q4 2023

Feb 09, 2024

BUY
$31.87 - $40.71 $12,748 - $16,284
400 New
400 $16,000
Q2 2023

May 20, 2024

SELL
$37.4 - $44.52 $2,992 - $3,561
-80 Reduced 89.89%
9 $0
Q2 2023

Aug 04, 2023

BUY
$37.4 - $44.52 $336 - $400
9 New
9 $0
Q3 2022

Nov 10, 2022

SELL
$42.27 - $57.6 $1,310 - $1,785
-31 Reduced 46.97%
35 $1,000
Q1 2022

Apr 28, 2022

BUY
$51.32 - $68.5 $923 - $1,233
18 Added 37.5%
66 $4,000
Q4 2021

Jan 20, 2022

BUY
$47.03 - $57.12 $1,504 - $1,827
32 Added 200.0%
48 $3,000
Q3 2021

Nov 02, 2021

BUY
$52.17 - $70.2 $52 - $70
1 Added 6.67%
16 $1,000
Q2 2021

Aug 06, 2021

BUY
$68.86 - $83.34 $413 - $500
6 Added 66.67%
15 $1,000
Q1 2021

Apr 23, 2021

SELL
$76.15 - $111.94 $7,310 - $10,746
-96 Reduced 91.43%
9 $1,000
Q4 2020

Feb 02, 2021

BUY
$96.85 - $148.25 $9,103 - $13,935
94 Added 854.55%
105 $10,000
Q3 2020

Oct 27, 2020

BUY
$122.47 - $213.56 $612 - $1,067
5 Added 83.33%
11 $2,000
Q1 2020

Apr 27, 2020

BUY
$143.0 - $274.03 $858 - $1,644
6 New
6 $1,000
Q4 2018

Feb 05, 2019

SELL
$87.81 - $110.65 $1,756 - $2,213
-20 Closed
0 $0
Q2 2018

Jul 30, 2018

BUY
$88.4 - $105.34 $1,768 - $2,106
20 New
20 $1,000

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.69B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.